PE20050481A1 - Nuevas formas cristalinas de {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona - Google Patents

Nuevas formas cristalinas de {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona

Info

Publication number
PE20050481A1
PE20050481A1 PE2004001008A PE2004001008A PE20050481A1 PE 20050481 A1 PE20050481 A1 PE 20050481A1 PE 2004001008 A PE2004001008 A PE 2004001008A PE 2004001008 A PE2004001008 A PE 2004001008A PE 20050481 A1 PE20050481 A1 PE 20050481A1
Authority
PE
Peru
Prior art keywords
pyridin
bistrifluoromethylbenzyl
triazol
chlorophenyl
crystalline forms
Prior art date
Application number
PE2004001008A
Other languages
English (en)
Inventor
Shella Lenyonga Tameze
Pamela Kaye Footman
Carsten Timpe
David Scott Coffey
Carsten Weber
Alfio Borghese
Steven Wayne Pedersen
Susan Marie Reutzel-Edens
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20050481A1 publication Critical patent/PE20050481A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A FORMAS CRISTALINAS DE {2-[1-(3,5-BISTRIFLUOROMETILBENCIL)-5-PIRIDIN-4-IL-1H-[1,2,3]TRIAZOL-4-IL]-PIRIDIN-3-IL}-(2-CLOROFENIL)-METANONA, COMPOSICIONES DE LAS MISMAS, PROCEDIMIENTOS DE ELABORACION DE ESTAS Y DE SUS INTERMEDIOS
PE2004001008A 2003-10-24 2004-10-20 Nuevas formas cristalinas de {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona PE20050481A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24

Publications (1)

Publication Number Publication Date
PE20050481A1 true PE20050481A1 (es) 2005-09-20

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004001008A PE20050481A1 (es) 2003-10-24 2004-10-20 Nuevas formas cristalinas de {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona

Country Status (28)

Country Link
US (1) US7381826B2 (es)
JP (1) JP4959336B2 (es)
KR (1) KR100848407B1 (es)
CN (1) CN1863791B (es)
AR (1) AR046131A1 (es)
AT (1) ATE462700T1 (es)
AU (1) AU2004285855B8 (es)
BR (1) BRPI0415010B8 (es)
CA (1) CA2542140C (es)
CL (2) CL2009001310A1 (es)
CR (1) CR8353A (es)
DE (1) DE602004026333D1 (es)
DK (1) DK1675846T3 (es)
EA (1) EA008881B1 (es)
EC (1) ECSP066517A (es)
ES (1) ES2340772T3 (es)
HR (1) HRP20100207T1 (es)
IL (1) IL174926A0 (es)
MA (1) MA28329A1 (es)
MY (1) MY157375A (es)
NO (1) NO335090B1 (es)
NZ (2) NZ545917A (es)
PE (1) PE20050481A1 (es)
PT (1) PT1675846E (es)
TW (1) TW200524906A (es)
UA (1) UA82901C2 (es)
WO (1) WO2005042515A1 (es)
ZA (1) ZA200603234B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200970604A1 (ru) 2006-12-20 2009-10-30 Эли Лилли Энд Компани Новое промежуточное соединение и способ, используемый для получения {2-[1-(3,5-бис-трифторметилбензил)-5-пиридин-4-ил-1н-[1,2,3]триазол-4-ил]пиридин-3-ил}-(2-хлорфенил)метанона
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
RU2770050C2 (ru) 2015-03-04 2022-04-14 Ванда Фармасьютиклз Инк. Способ лечения с применением традипитанта
US10287287B2 (en) 2015-08-17 2019-05-14 Eli Lilly And Company Process development of a pyridine-containing NK-1 receptor antagonist
US11549147B2 (en) 2017-09-13 2023-01-10 Vanda Pharmaceuticals Inc. Treatment of atopic dermatitis with tradipitant
CN111343981A (zh) 2017-11-17 2020-06-26 万达制药公司 使用川地匹坦治疗胃肠疾病的方法
EP3801514A1 (en) 2018-06-08 2021-04-14 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
JP7468964B2 (ja) 2018-09-28 2024-04-16 バンダ・ファーマシューティカルズ・インコーポレイテッド 動揺病におけるトラジピタントの使用
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CA3169449A1 (en) 2020-02-25 2021-09-02 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
US20230145932A1 (en) 2020-03-26 2023-05-11 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
EP4395778A1 (en) 2021-08-31 2024-07-10 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2024138040A1 (en) 2022-12-21 2024-06-27 Vanda Pharmaceuticals Inc. Methods of treatment with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
ATE333879T1 (de) * 1996-10-07 2006-08-15 Merck Sharp & Dohme Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
CZ2002534A3 (cs) * 1999-08-13 2002-07-17 Vertex Pharmaceuticals Incorporated Inhibitory protein-kináz, farmaceutické prostředky, které je obsahují, a jejich pouľití
CA2388202A1 (en) 1999-10-29 2001-05-10 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) * 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
PE20040600A1 (es) * 2002-04-26 2004-09-15 Lilly Co Eli Derivados de triazol como antagonistas del receptor de taquicinina

Also Published As

Publication number Publication date
HRP20100207T1 (hr) 2010-05-31
JP4959336B2 (ja) 2012-06-20
CA2542140A1 (en) 2005-05-12
KR20060061388A (ko) 2006-06-07
US20070078166A1 (en) 2007-04-05
BRPI0415010A8 (pt) 2018-05-08
CN1863791B (zh) 2011-12-07
NO335090B1 (no) 2014-09-08
JP2007509143A (ja) 2007-04-12
MA28329A1 (fr) 2006-12-01
ES2340772T3 (es) 2010-06-09
IL174926A0 (en) 2006-08-20
WO2005042515A1 (en) 2005-05-12
AU2004285855A1 (en) 2005-05-12
BRPI0415010B8 (pt) 2021-05-25
AR046131A1 (es) 2005-11-23
NZ545917A (en) 2009-11-27
NO20062371L (no) 2006-05-24
CR8353A (es) 2006-06-06
CL2009001310A1 (es) 2009-12-04
BRPI0415010B1 (pt) 2019-07-09
CN1863791A (zh) 2006-11-15
TW200524906A (en) 2005-08-01
NZ580480A (en) 2010-02-26
CL2009001311A1 (es) 2009-10-02
DK1675846T3 (da) 2010-05-31
EA200600829A1 (ru) 2006-08-25
US7381826B2 (en) 2008-06-03
EA008881B1 (ru) 2007-08-31
BRPI0415010A (pt) 2006-11-07
ECSP066517A (es) 2006-10-10
AU2004285855B8 (en) 2011-04-28
KR100848407B1 (ko) 2008-07-28
DE602004026333D1 (de) 2010-05-12
MY157375A (en) 2016-06-15
UA82901C2 (en) 2008-05-26
ATE462700T1 (de) 2010-04-15
PT1675846E (pt) 2010-04-20
AU2004285855B2 (en) 2010-12-23
ZA200603234B (en) 2007-07-25
CA2542140C (en) 2012-05-29

Similar Documents

Publication Publication Date Title
PE20050481A1 (es) Nuevas formas cristalinas de {2-[1-(3,5-bistrifluorometilbencil)-5-piridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona
ATE428701T1 (de) Kristalline form von bisä(e)-7-ä4-(4-fluorphenyl)-6-isopropyl-2-
CR8475A (es) Fenilalanina-amidas sustituidas por benzoilo
ITVR20020062A1 (it) Preparazione estemporanea di periossiacidi organici stabili nel tempo
ECSP066467A (es) Formas Polimórficas de 3-(4-amino-1-Oxo-1-3 DIhidroisoindol-2-IL)-Piperidin-2,6-Diona
RS20060317A (en) Derivatives of n-/phenyl(alkylpiperidine-2-yl)methyl/ benzamide, preparation method thereof and application of same in therapeutics
DK1673370T3 (da) Krystallingsk form af linezolid
CR8312A (es) Nuevas sulfonamidas como agentes fitosanitarios
IS8307A (is) Fenýl eða pýridýl amíð efnasambönd sem prostaglandín E2 mótlyf
DE602005016297D1 (de) Antithrombotische diamide
HRP20050662A2 (en) Viral polymerase inhibitors
RS52117B (en) DIASTEREO-SELECTIVATE SYNTHESIS OF EGZO ANALOGUE IN HIMBAC
UY29369A1 (es) Nueva sal de 1-(-3-(3-(4-clorofenil) propoxi(propil) -piperidina
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
RS52260B (en) N- (2-hydroxyethyl) -N-methyl-4- (quinoline-8-yl (1- (thiazol-4-ylmethyl) piperidin-4-ylidene) methyl) benzamide, a process for its production as well as its use for treatment PAIN, TENSION AND DEPRESSION
DK1687263T3 (da) Cis-trans-isomerisering af semicarbazonforbindelser
DK1463731T3 (da) Dibenzodiazepinderivater, deres fremstilling og anvendelse
DK1660485T3 (da) Forbedret fremgangsmåde til fremstilling af alpha-polymorfisk eletriptanhydrobromid
PE20040160A1 (es) 1,2-dihidropirazol-3-onas que controlan citoquinas inflamatorias
EA200600138A1 (ru) Способ получения кристаллического полиморфа ингибитора агрегации тромбоцитов
ITMC20030085A1 (it) Cassaforma componibile per lo stampaggio dei cubetti di
ATE499348T1 (de) Stabiler polymorph von bifeprunoxmesilat
UY28145A1 (es) Nuevos compuestos farmaceuticos
FR2864109B1 (fr) Croissance organisee de nano-structures
ECSP034459A (es) Proceso para la preparacion de discodermolida y sus analogos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed